Am Heart J. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 patients.
Eur Heart J. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Cerebrovascular events in 21 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction J Am Coll Cardiol. Edoxaban vs. Circ J. J Am Heart Assoc. Am J Med.
J Am Soc Echocardiogr. Eur J Heart Fail. In a subgroup analysis, low-dose edoxaban significantly reduced stroke or systemic embolism compared with warfarin in patients taking concomitant amiodarone. Edoxaban resulted in a significant dose-related reduction in bleeding when compared with warfarin, although high-dose edoxaban resulted in an excess of GI bleeding.
This is likely because of excessive renal clearance of the drug in these patients correlated with drug trough levels in this analysis. This does not apply for use in venous thromboembolism treatment. Although there are subtle differences between the four agents and these trials, the current overall evidence supports safety and efficacy of all four agents when compared with warfarin for stroke prophylaxis in patients with AF.
Direct head-to-head comparisons and cost-effectiveness analyses are eagerly awaited. Among Asian patients, there is a higher likelihood of achieving lower edoxaban trough levels and anti-factor Xa levels, suggesting that the higher dose may be more appropriate. J Am Coll Cardiol ; Eur Heart J ; Eur Heart J ;Jan 8:[Epub ahead of print]. Circulation ; Lancet ; Edoxaban vs.
Eur Heart J ;May [Epub ahead of print]. N Engl J Med ; Presented by Dr. This card is not insurance and does not cover deductibles. This offer is not conditioned on any past, present, or future purchases, including refills. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by patients through this offer.
This is not insurance. Pharmacist Conditions: By using this card, you certify that the Eligibility Criteria are met. Applicable discounts will be displayed in the transaction response. Claims submitted utilizing the program are subject to audit or validation. Daiichi Sankyo, Inc.
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. Nvaf Study Design Clinical Studies. Study endpoints 1 Primary efficacy The occurrence of first stroke either ischemic or hemorrhagic or of an SE that occurred during treatment or within 3 days from the last dose taken. Primary safety Major bleeding that occurred during or within 2 days of stopping study treatment. Nvaf Study Design - Page Navigation.
0コメント